Comparative assessment of lipid effects of endocrine therapy for breast cancer: Implications for cardiovascular disease prevention in postmenopausal women

Breast

Volumn 15, Issue 3, 2006, Pages 301-312

  Esteva, F J ^a   Hortobagyi, G N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Cardiovascular disease; Endocrine therapy; Lipid; Postmenopausal

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; APOLIPOPROTEIN B; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; FULVESTRANT; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGESTROL ACETATE; PLACEBO; TAMOXIFEN; TAMOXIFEN CITRATE; TRIACYLGLYCEROL;

ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEVELOPED COUNTRY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN SYNTHESIS; EXPERIENCE; FEMALE; HEART PROTECTION; HORMONAL THERAPY; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MEDICAL ASSESSMENT; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 33744534911     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2005.08.033     Document Type: Article

References (74)

1. National Center for Chronic Disease Prevention and Health Promotion. http://www.cdc.gov/nccdphp/bb_heartdisease/index.htm 2004.
2. Lerner D.J., and Kannel W.B. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 111 (1986) 383-390
3. Stampfer M.J., and Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 20 (1991) 47-63
4. Rosano G.M., Kaski J.C., Arie S., et al. Failure to demonstrate myocardial ischaemia in patients with angina and normal coronary arteries. Evaluation by continuous coronary sinus pH monitoring and lactate metabolism. Eur Heart J 17 (1996) 1175-1180
5. Furberg A.S., Veierod M.B., Wilsgaard T., Bernstein L., and Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 96 (2004) 1152-1160
6. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
7. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
9. Jordan V.C. Estrogens and antiestrogens. In: Bast R.C., Kufe D.W., Pollock R.E., Weichselbaum R.R., Holland J.F., and Frei III E. (Eds). Cancer medicine (2000), BC Dekker, Hamilton, Canada 743-750
10. Cutuli B., Petit J.C., Fricker J.P., et al. Adjuvant tamoxifen in breast cancer treatment in postmenopausal women: occurrence of thromboembolic complications. Oncol Rep 1 (1994) 59-63
11. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88 (1996) 1529-1542
12. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
13. Meier C.R., and Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45 (1998) 608-612
14. Johnston S.R. Acquired tamoxifen resistance in human breast cancer-potential mechanisms and clinical implications. Anticancer Drugs 8 (1997) 911-930
15. Partridge A.H., Wang P.S., Winer E.P., and Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21 (2003) 602-606
16. Howell A., Robertson J.F.R., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 (2002) 3396-3403
17. Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20 (2002) 3386-3395
18. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18 (2000) 3758-3767
19. Bonneterre J., Thürlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18 (2000) 3748-3757
20. Bonneterre J., Buzdar A., Nabholtz J.M., et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92 (2001) 2247-2258
21. Nabholtz J.M., Bonneterre J., Buzdar A., et al. Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39 (2003) 1684-1689
22. Buzdar A., Jonat W., Howell A., et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 14 (1996) 2000-2011
23. Buzdar A.U., Jonat W., Howell A., et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83 (1998) 1142-1152
24. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19 (2001) 2596-2606
25. Buzdar A., Douma J., Davidson N., et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19 (2001) 3357-3366
26. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21 (2003) 2101-2109
27. European Organisation for Research and Treatment of Cancer. EORTC protocols. http://www.eortc.be/protoc/listprot.asp?kind=group&grp=2 2004. 18-3-0004.
28. Kaufmann M., Bajetta E., Dirix L.Y., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18 (2000) 1399-1411
29. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
30. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
31. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 (2003) 1802-1810
32. BIG 1-98 Collaborative Group. BIG 1-98: a prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. The Breast 14 Suppl 1 (2005) S3
33. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
34. Jakesz R., Kaufmann M., Gnant M., Jonat W., Mittleboek M., Greil R., et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 88 Suppl 1 (2004) S7
35. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23 (2005) 5138-5147
36. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 349 (2003) 1793-1802
37. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Updated analysis of the NCIC CTG MA17 randomized placebo (P) controlled trial of letrozole (L) after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Proc Am Soc Clin Oncol 23 (2004) 87
38. Jakesz R., Samonigg H., Greil R., Gnant M., Schmid M., Kwasny W., et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Proc Am Soc Clin Oncol 23 16s part I of II (2005) 10s
39. Anderson K.M., Castelli W.P., and Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 257 (1987) 2176-2180
40. Martin M.J., Hulley S.B., Browner W.S., Kuller L.H., and Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 2 (1986) 933-936
41. Wilson P.W., Garrison R.J., Castelli W.P., et al. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol 46 (1980) 649-654
42. Assmann G., Schulte H., von Eckardstein A., and Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 Suppl (1996) S11-S20
43. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
44. Abbott R.D., Donahue R.P., Kannel W.B., and Wilson P.W. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 260 (1988) 3456-3460
45. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
46. Farnier M., and Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 82 (1998) 3J-10J
47. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251 (1984) 351-364
48. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251 (1984) 365-374
49. Stamler J., Wentworth D., and Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256 (1986) 2823-2828
50. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 (1998) 7B-12B
51. Assmann G., Schulte H., Funke H., and von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 19 Suppl M (1998) M8-M14
52. Grundy S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 81 (1998) 18B-25B
53. Shlipak M.G., Chaput L.A., Vittinghoff E., et al. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). Am Heart J 146 (2003) 870-875
54. Bertelli G., Pronzato P., Amoroso D., et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 12 (1988) 307-310
55. Dewar J.A., Horobin J.M., Preece P.E., et al. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 305 (1992) 225-226
56. Love R.R., Wiebe D.A., Feyzi J.M., Newcomb P.A., and Chappell R.J. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86 (1994) 1534-1539
57. Morales M., Santana N., Soria A., et al. Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer. Breast Cancer Res Treat 40 (1996) 265-270
58. Hozumi Y., Kawano M., Saito T., and Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 83 (1998) 1633-1635
59. Brun L.D., Gagne C., Rousseau C., Moorjani S., and Lupien P.J. Severe lipemia induced by tamoxifen. Cancer 57 (1986) 2123-2126
60. Liu C.L., and Yang T.L. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat 79 (2003) 11-16
61. Fisher B., Dignam J., Bryant J., and Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 (2001) 684-690
62. Cuzick J. Aromatase inhibitors in prevention-data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163 (2003) 96-103
63. Wojtacki J., Lesniewski-Kmak K., Pawlak W., and Nowicka E. Anastrozole therapy and lipid profile: an update. Eur J Cancer Suppl 2 (2004) 142
64. Dewar J., Nabholtz J.-M.A., Bonneterre J., Buzdar A., Robertson J.F.R., Thurlimann B., et al. The effect of anastrozole (Arimidex™) on serum lipids-data from a randomized comparison of anastrozole (AN) vs Tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res Treat 64 Suppl (2000) S51
65. Elisaf M.S., Bairaktari E.T., Nicolaides C., et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37 (2001) 1510-1513
66. Engan T., Krane J., Johannessen D.C., Lønning P.E., and Kvinnsland S. Plasma changes in breast cancer patients during endocrine therapy-lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 36 (1995) 287-297
67. Atalay G., Dirix L., Biganzoli L., et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 15 (2004) 211-217
68. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16 (1998) 453-461
69. Sawada S., and Sato K. Effect of anastrozole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer. Breast Cancer Res Treat 82 Suppl 1 (2003) S31-S32
70. Hozumi Y., Saito T., Inoue K., Shiozawa M., Omoto Y., Tabei T., et al. Effects of anastrozole on the lipid profile in postmenopausal breast cancer patients-a preliminary study. Eur J Cancer Suppl 2 (2004) 143
71. Kataja V., Hietanen P., Joensuu H., Ala-Luhtala T., Asola R., Kokko R., et al. The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer-a randomised study. Breast Cancer Res Treat 76 Suppl 1 (2002) S156
72. Mendelsohn M.E., and Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 340 (1999) 1801-1811
73. Schuit S.C., Oei H.H., Witteman J.C., et al. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA 291 (2004) 2969-2977
74. Shearman A.M., Cupples L.A., Demissie S., et al. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 290 (2003) 2263-2270